Biotech startups in Shanghai, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| Drug Farm | Shanghai | Series D | $55.0M | 2026-07-13 |
| Degron Therapeutics | Shanghai | Series A | $40.0M | 2026-05-14 |
| MindRank AI | Shanghai | Series B | $52.0M | 2026-07-08 |
| Bluesail Surgical | Shanghai | Series B | $104.5M | 2026-09-23 |
| Full-Life Technologies | Shanghai | Series D | $109.0M | 2026-05-18 |
| Phrontline Biopharma | Shanghai | Seed | $60.0M | 2025-11-21 |
| Bivision | Shanghai | Series B | $58.8M | 2026-05-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 229 biotech startups in Shanghai, China have raised $8.0B in total.
- 40 of them closed their most recent round in the last 12 months, $1.6B combined.
- The largest of those rounds is Anew Labs' $290.0M Series A, dated September 2026.
- The most recent is Active Technology's $69.4M angel round on 4 November 2026.
- Qiming Venture Partners is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 194 companies (85%).
- 38% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (41% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
16 of 229| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
| Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
| Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| Phrontline Biopharma | Phrontline Biopharma develops antibody-drug conjugate products to treat cancer. | Biotech | Seed | $60.0M | 2025-11-21 | $73.8M | Decheng Capital, Med-Fine Capital | 11 to 50 | 2022 |
| Brise Pharma | Brise Pharma provides scientific research and technical services in the pharmaceutical field. | Biotech | Series A | $28.1M | 2025-11-11 | $228.3M | Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 | 11 to 50 | 2021 |
| GRIT Biotechnology | GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. | Biotech | Series C | $84.0M | 2025-10-14 | $153.5M | Matrix Partners China, Hillhouse Investment, CICC +2 | 51 to 100 | 2019 |
| Meiyou Technology | Meiyou Technology develops DNA synthesizers using enzymatic technology for long-fragment DNA synthesis and splicing. | Biotech | Angel | $1.4M | 2024-06-28 | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2023 |
Table 1. Biotech startups in Shanghai, China: the 16 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 229.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CORXEL Pharmaceuticals | CORXEL Pharmaceuticals develops medicines for underserved patients. | Biotech | Series D | $287.0M | 2026-01-22 | $451.8M | Leaps by Bayer, RTW Investments | 51 to 100 | 2019 |
| 2 | Full-Life Technologies | Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. | Biotech | Series D | $109.0M | 2026-05-18 | $337.3M | Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 | 51 to 100 | 2021 |
| 3 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 4 | Phrontline Biopharma | Phrontline Biopharma develops antibody-drug conjugate products to treat cancer. | Biotech | Seed | $60.0M | 2025-11-21 | $73.8M | Decheng Capital, Med-Fine Capital | 11 to 50 | 2022 |
| 5 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 6 | Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners, South China Venture Capital, BVCF +1 | 101 to 250 | 2015 |
| 7 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 8 | Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| 9 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| 10 | Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
Table 2. Biotech startups in Shanghai, China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 5 | 2% | 1 | Novamab |
| 2 | Sherpa Healthcare Partners | Venture capital firm | Beijing, China | 4 | 2% | 1 | MindRank AI |
| 3 | MiraclePlus | Startup accelerator | Haidian, China | 3 | 1% | 1 | SynMetaBio |
| 4 | Legend Capital | Venture capital firm | Beijing, China | 3 | 1% | 2 | Alioth, Allink Biotherapeutics |
| 5 | Matrix Partners China | Venture capital firm | Beijing, China | 3 | 1% | 1 | Alioth |
| 6 | Taiyu Investment | Venture capital firm | Beijing, China | 3 | 1% | 1 | Novamab |
| 7 | BioVenture | Venture capital firm | Suzhou, China | 2 | 1% | 2 | Degron Therapeutics, Allink Biotherapeutics |
| 8 | New Alliance Capital | Private equity firm | Shanghai, China | 2 | 1% | 1 | Degron Therapeutics |
| 9 | Med-Fine Capital | Venture capital firm | Shanghai, China | 2 | 1% | 2 | Degron Therapeutics, Phrontline Biopharma |
| 10 | Huagai Capital | Private equity firm | Beijing, China | 2 | 1% | 2 | Bluesail Surgical, MindRank AI |
| 11 | Chengwei Capital | Venture capital firm | Shanghai, China | 2 | 1% | 1 | Full-Life Technologies |
| 12 | Decheng Capital | Venture capital firm | Menlo Park, United States | 2 | 1% | 1 | Phrontline Biopharma |
| 13 | Gaorong Capital | Venture capital firm | Wangjing, China | 2 | 1% | 2 | Bivision, Allink Biotherapeutics |
| 14 | Kaitai Capital | Venture capital firm | Hangzhou, China | 2 | 1% | 1 | Bivision |
| 15 | Linear Capital | Venture capital firm | Shanghai, China | 2 | 1% | 1 | SynMetaBio |
Table 3. Biotech startups in Shanghai, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 194 | 85% | $7.3B |
| Software | 15 | 7% | $532.1M |
| Artificial intelligence | 13 | 6% | $532.1M |
| Hardware | 6 | 3% | |
| Fintech | 1 | 0% | |
| Commerce | 1 | 0% | |
| Energy | 1 | 0% |
Table 4. Biotech startups in Shanghai, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Shanghai, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 4 | 10% | $99.5M |
| September 2026 | 5 | 12% | $514.5M |
| August 2026 | 1 | 2% | |
| July 2026 | 7 | 18% | $190.4M |
| June 2026 | 1 | 2% | |
| May 2026 | 5 | 12% | $244.6M |
| April 2026 | 2 | 5% | $58.5M |
| March 2026 | 3 | 8% | $21.4M |
| February 2026 | 1 | 2% | |
| January 2026 | 5 | 12% | $315.7M |
| December 2025 | 5 | 12% | $119.7M |
| November 2025 | 1 | 2% | $60.0M |
Table 6. Biotech startups in Shanghai, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 34 | 15% | $1.4B |
| 2025 | 34 | 15% | $959.8M |
| 2024 | 20 | 9% | $62.7M |
| 2023 | 26 | 11% | $235.3M |
| 2022 | 29 | 13% | $738.1M |
| 2021 | 35 | 15% | $1.4B |
Table 7. Biotech startups in Shanghai, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 17 | 8% |
| 2020 to 2022 | 68 | 30% |
| 2015 to 2019 | 81 | 36% |
| 2010 to 2014 | 39 | 17% |
| Before 2010 | 21 | 9% |
Table 8. Biotech startups in Shanghai, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 16 | 8% |
| 11 to 50 | 81 | 41% |
| 51 to 100 | 43 | 22% |
| 101 to 250 | 27 | 14% |
| 251 to 500 | 14 | 7% |
| 501 to 1,000 | 9 | 5% |
| 1,001 to 5,000 | 4 | 2% |
| 5,001 to 10,000 | 2 | 1% |
Table 9. Biotech startups in Shanghai, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Shanghai, China. On 16 November 2026 that is 229 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 16 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 229 rows: 80 have no round amount, 0 no city and 76 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Shanghai, China are on the list?
- 229, in the file dated 16 November 2026. 40 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 229 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.